7UX

Spago Nanomedical DB:7UX Stock Report

Last Price

€0.062

Market Cap

€6.3m

7D

-6.1%

1Y

-84.1%

Updated

07 Feb, 2023

Data

Company Financials +

7UX Stock Overview

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden.

7UX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Spago Nanomedical AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Spago Nanomedical
Historical stock prices
Current Share Pricekr0.062
52 Week Highkr0.39
52 Week Lowkr0.049
Beta1.87
1 Month Change12.73%
3 Month Change-38.00%
1 Year Change-84.06%
3 Year Changen/a
5 Year Changen/a
Change since IPO-91.53%

Recent News & Updates

Recent updates

Shareholder Returns

7UXDE BiotechsDE Market
7D-6.1%-0.3%1.8%
1Y-84.1%5.7%-8.4%

Return vs Industry: 7UX underperformed the German Biotechs industry which returned 6% over the past year.

Return vs Market: 7UX underperformed the German Market which returned -7.1% over the past year.

Price Volatility

Is 7UX's price volatile compared to industry and market?
7UX volatility
7UX Average Weekly Movement16.8%
Biotechs Industry Average Movement5.7%
Market Average Movement5.2%
10% most volatile stocks in DE Market10.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 7UX is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: 7UX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199915Mats Hansenhttps://spagonanomedical.se

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.

Spago Nanomedical AB (publ) Fundamentals Summary

How do Spago Nanomedical's earnings and revenue compare to its market cap?
7UX fundamental statistics
Market Cap€6.26m
Earnings (TTM)-€3.44m
Revenue (TTM)€566.91k

11.0x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
7UX income statement (TTM)
Revenuekr6.46m
Cost of Revenuekr20.35m
Gross Profit-kr13.89m
Other Expenseskr25.30m
Earnings-kr39.20m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.43
Gross Margin-215.06%
Net Profit Margin-606.76%
Debt/Equity Ratio0%

How did 7UX perform over the long term?

See historical performance and comparison